Compare Gilead Sciences, Inc. (GILD) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $149.89 (market cap $182.40B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $92.76 (market cap $5.86B). The key difference: Gilead Sciences, Inc. is far larger — about 31.1× State Street SPDR Bloomberg High Yield Bond ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and State Street SPDR Bloomberg High Yield Bond ETF for 60 Days on average.
| GILD | JNK | |
|---|---|---|
Market Cap | $182.40B | $5.86B |
Volume | 4,469,821 | 7,780,002 |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $98.02 |
52-Week Low | $116.74 | $92.30 |
Typical Hold Time | 111 Days | 60 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
JNK trades at $92.695 with a slight 0.07% decline, showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions of $0.53 per share through mid-2026. Recent market focus centers on high-yield bond dynamics amid rising Treasury yields and institutional positioning changes.
The high-yield bond ETF faces headwinds from rising interest rates but benefits from institutional accumulation. Key risks include bond market volatility and economic sensitivity, while the consistent dividend stream provides income appeal for yield-seeking investors in the current rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
